possible itching) numeric rating scale, recorded daily during the first 2 weeks of treatment and at clinic visits. Mediation modeling was used to determine the relationship between ISS, the Physician’s Global Assessment (PGA), a clinical measure of psoriasis severity assessing erythema, induration, and scaling, and treatments (n = 35). Mediation modeling included ISS as the dependent variable (averaged post-treatment ISS during weeks 2-12 for every patient), PGA as the mediator variable (averaged post-treatment PGA score during weeks 2-12 for every patient), and treatments (with each drug dose compared with placebo) as the independent variable. Sensory psychometric analyses were performed on ISS using post-baseline assessments. RESULTS: The direct effects of all CP-690,550 doses on ISS were 70%-81% (vs placebo; p < 0.001), indicating that drug effects on pruritus were mostly independent of improvements in erythema, induration, and scaling. Daily ISS measurements had acceptable test-retest reliability (intraclass correlation: 0.83) in patients who did not change on PGA during the first 2 weeks of the trial. Pearson correlations between ISS and other measures were consistent with expectations; for example, weekly ISS correlated with weekly PGA (range: 0.3–0.5) and Patient Global Assessment (range: 0.6–0.7). CONCLUSIONS: In patients with psoriasis, CP-690,550 has a direct, beneficial effect on patient-reported pruritus that is independent from improvements in clinician-reported psoriasis severity. Post-baseline assessments of ISS showed favorable psychometric characteristics, indicating its potential use as a simple tool for assessment of pruritus in clinical trials.

PSS21
GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
Dennise-Sommers B1, Galipeau N1, Fitzgerald R1, Evans C2, Daniels S3, Burgess SM4
1MAPI Values, Boston, MA, USA, 2Allergan, Inc., Irvine, CA, USA
OBJECTIVES: To identify an existing patient-reported outcome (PRO) measure to substantiate labeling or promotional claims for treatment in alopecia. METHODS: MEDEICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE USE: RESULTS FOR ALOPECIA
PSS22
SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN WITH ATOPIC DERMATITIS
Iskedjian M1, Navarro V2, Khondoker F3, Farah B4
1PharmIdeas Research and Consulting, Oakville, ON, Canada, 2PharmIdeas Europe SAS, Lyon, France, 3PharmIdeas Research and Consulting, Ottawa, ON, Canada
OBJECTIVES: A systematic review of the literature was performed to elicit the published evidence relating to quality of life (QOL) in children with atopic dermatitis (AD). METHODS: OVID MEDLINE® and EMBASE® were explored by two reviewers for a combined search with terms related to economics and QOL in a paediatric population, for the period 1996-2010. This review reports the results of the MEDLINE review. Two reviewers browsed abstracts, retrieved suitable articles and summarized key findings. A third person acted as overall reviewer and adjudicator in case of disagreement. RESULTS: From an initial search yielding 704 references, 51 primary research articles were included in the review, 44 reporting on QOL as primary outcome and 37 as secondary outcome. QOL as a primary outcome was reported for Europe (n = 7), North America (n = 4), Asia (n = 3), Australia (n = 1), Brazil and South America (n = 3). One study reported preference-based outcomes. Most studies were based on AD-specific items. The Children’s Dermatology Life Quality Index (CDLQI), the Dermatology Life Quality Index (DLQI), the Quality of Life Index (QoLI), and the Quality of Life Index for Atopic Dermatitis were among the most widely used QOL measures, with most studies pointing to an inverse correlation between QOL and severity as well as correlation between various instruments. Studies reporting on QOL as a secondary outcome confirmed those findings. CONCLUSIONS: There is a clear lack of studies eliciting health state utilities. Furthermore, most AD-specific tools do not provide a standard, quantitative measurement in relation to perfect health as would do preference based studies required for cost-utility analyses. Further research should focus on utility measurement.

Sensory Systems Disorders – Health Care Use & Policy Studies

PSS23
COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS
Naim A1, Pitts J2, Chen CV3, Wright D2, Chalk MB4, Edington D3
1Centers for Ortho Biotech Services, LLC, Endon, PA, USA, 2Centers for Ortho Biotech Services, LLC, Piney, PA, USA, 3Chalk & Associates, Austin, TX, USA, 4University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Psoriasis (PsO) is a chronic, epidermal, immunological skin disease that affects approximately 2-2.5% of US population. It may result in work productivity loss and high overall healthcare costs for employers. However, the impact of health-risks is not well studied. We compared health-risks, lost productivity, and total direct healthcare costs among individuals with PsO and five most prevalent chronic conditions. METHODS: Health-risk information and self-reported illness days using health-risk assessment (HRA) data were examined and direct Healthcare costs (medical and pharmacy) using claims data for employees, retirees, and their adult dependents of a large self-insured employer were compared from 2002-2006 among individuals with RA and five most prevalent chronic conditions; asthma, coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hypertension, chronic obstructive pulmonary disease (COPD). RESULTS: 54 individuals with PsO were identified. The PsO cohort had moderate health-risk score (2.8/5) which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension (2.6) and lower than diabetes (3.3/5) and COPD (3.4/5). A higher proportion (53.5%) of individuals with PsO had >50 annual days per year compared with individuals with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes (28.4%), and COPD (33%). Annual direct healthcare costs were also higher for individuals with RA ($28,933) as compared to individuals with asthma ($25,814), CAD/CHF ($22,916), hypertension ($18,632), and diabetes ($18,204), and did not differ significantly compared to individuals with COPD ($38,839). CONCLUSIONS: Individuals with PsO have similar health-risks but higher illness days, and direct healthcare costs as compared to the individuals with five most prevalent chronic conditions. Psoriasis is a high cost and lost productivity driver for employers. Population health based programs that engage employees in appropriately managing their chronic conditions can help employers reduce health-risks, improve productivity, and may help reduce healthcare costs as well.

PSS24
MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE UNITED STATES
Patel P1, Lim HC2, Feldman SR3, Fleischer AB4, Nahata M5, Balkrishnan R2
1University of Georgia, Athens, GA, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Wake Forest University, Winston-Salem, NC, USA, 4Ohio State University, Columbus, OH, USA
OBJECTIVES: Acne is a common condition for which multiple treatment options are available. The patterns of pharmacotherapy for acne and similar conditions, and the effect of those patterns on cost, are not well characterized. This study examined the impacts of patients’ treatment choices on annual healthcare costs for acne and acne related conditions on medication spending. Pharmacologic treatment of acne affects approximately 2-2.5% of US population. It may result in work productivity loss and high overall healthcare costs for employers. However, the impact of health-risks is not well studied. We compared health-risks, lost productivity, and total direct healthcare costs among individuals with PsO and five most prevalent chronic conditions; asthma, coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hypertension, chronic obstructive pulmonary disease (COPD). METHODS: A retrospective cross-sectional study was conducted using the 2007 Medical Expenditure Panel Survey (MEPS) database. Information on patient demographics, health status, medication utilization, and medical spending was obtained for the 3,784,816 patients with acne and similar conditions. RESULTS: Weighted linear regression analyses indicated that the use of topical retinoids was preferred in combination with other treatments rather than its monotherapy. Oral antibiotics were widely prescribed and its use was associated with a significant decrease in total annual prescription spending. Use of oral retinoids and oral contraceptives increased the annual prescription costs significantly. Increase in annual drug refills was not associated with the improvement in health status. CONCLUSIONS: We observed an association with medication choice for acne and acne related conditions on medication spending. Pharmacologic treatment of acne significantly adds to acne related annual healthcare costs compared to non pharmacologic treatment as well.

PSS25
MEDICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS
Ok HT1, Feldman SR2, Balkrishnan R2
1University of Michigan College of Pharmacy, Ann Arbor, MI, USA, 2Wake Forest University, Winston-Salem, NC, USA, 3University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To identify factors that predict adherence to topical medication in pediatric population with atopic dermatitis (AD), and assess their impact on healthcare expenditures. METHODS: AD patient’s age under 12 years old using topical corticosteroid or topical calcineurin inhibitor (TCI) was identified using MarketScan Medicaid database for 2007 to 2010. Adherence analysis was carried to examine predictors for medication adherence and their predictions on healthcare costs. RESULTS: 4,182 patients were included, with a mean age of 4 years. Adherence to AD medication average was low (41%), with the lowest rates in patients with low potency corticosteroid therapy alone including alclometasone, desonide or hydrocortisone (39%) and the highest rates in patients with high potency corticosteroid therapy alone including triamcinolone, beclomethasone, and their combinations.